Promoting Healthcare Innovation

With a focus on the Psychiatry & Neurology and Oncology as priority disease areas, Sumitomo Pharma Group will contribute to
improving not just the treatments of patients but also the QOL (quality of life) of patients and their families, through diverse
approaches, including pharmaceutical products, regenerative medicine/cell therapy, and non-pharmaceutical solutions.